Primary open angle glaucoma (POAG) is a chronic, progressive optic neuropathy characterized structurally by optic disc and retinal nerve fiber layer thinning and functionally by defects starting initially in the peripheral vision as measured by a visual field test. Recently, glaucoma has emerged as a leading cause of irreversible vision loss worldwide and is an issue of major public health importance. It is estimated to affect 66 million people worldwide, with at least 6.8 million people bilaterally blind from the condition ([@b38-ppa-2-303]). Individuals of African ancestry have a higher prevalence, earlier age of onset, and often a more aggressive form of POAG vs Caucasian populations ([@b29-ppa-2-303]; [@b40-ppa-2-303]; [@b14-ppa-2-303], [@b13-ppa-2-303]). Once diagnosed, it heralds the onset of lifelong therapy, careful monitoring of the optic disc and retinal nerve fiber layer (RNFL) for damage along with periodic visual field checks.

Currently the mainstay of treatment is reduction in intraocular pressure (IOP) enough to achieve a therapeutic goal termed the 'target IOP range' ([@b9-ppa-2-303]). This is the level of IOP at which further optic nerve and/or visual field damage is not expected to occur. There is now good evidence from randomized controlled trials that lowering IOP to target levels slows optic nerve and/or visual field damage ([@b2-ppa-2-303]; [@b23-ppa-2-303]; [@b30-ppa-2-303]; [@b33-ppa-2-303]). IOP also appears to be the only risk factor that can be easily modified and objectively monitored by eye care professionals such as ophthalmologists and optometrists thereby minimizing conversion rates of ocular hypertension (OHT) to glaucoma and disease progression in established glaucoma ([@b2-ppa-2-303]; [@b23-ppa-2-303]; [@b30-ppa-2-303]; [@b33-ppa-2-303]). Besides, appropriate and timely sharing of target IOP with patients and physician colleagues often helps to strengthen therapeutic and collegial relationships.

Treatment decisions and effects on quality of life
==================================================

Achieving target IOP range in POAG involves a fine balance between judicious use of medication and other strategies to lower IOP while simultaneously preserving patients' vision and ensuring an acceptable overall quality of life. Treatment is often initiated in a stepwise fashion beginning with topical drug therapy (single then multidrug combinations) followed by laser trabeculoplasty, and if needed, filtering surgery (trabecular meshwork or Schlemm's canal surgery, trabeculectomy, and implantation of shunts) aimed at draining aqueous humor from the eye ([@b1-ppa-2-303]; [@b28-ppa-2-303]). While caregivers are typically keen on achieving target IOPs, using maximum tolerated medications with least side effect profiles and deciding on the type of surgery the patient should undergo lest medications fail, we find our patients frequently have different goals. In one study, when 82 patients were questioned about their biggest anxiety related to therapy, without doubt most harbored concerns about immediate moderate visual impairment that could impact their freedom and the risk of blindness ([@b5-ppa-2-303]). Translated to the real world situation, their anxiety was about inability to work in certain occupations, restrictions to driving and involvement in motor vehicle accidents (MVA), apprehension of falls and deterioration in general health status, and last but not the least, fear of eventual blindness ([@b18-ppa-2-303]). When probed further, other disturbing misconceptions regarding glaucoma therapy were revealed. About half of established glaucoma patients believed that symptoms would warn them of disease progression, about one-third of new patients considered blindness to be a common outcome of glaucoma and most patients thought that topical medications did not have any systemic side-effects ([@b10-ppa-2-303]). In many ways, it is a gentle reminder that long-term therapy also entails quality of life (QOL) issues. A study that evaluated these QOL issues categorized patients mainly into two groups based on their main priorities as "reading and seeing detail" and "outdoor mobility", the latter changing to the former with increasing visual field loss and an increased willingness to trade time off for therapy thus resulting in a situation of forced compliance ([@b3-ppa-2-303]). Considering this, it is remarkable how, the entire viewpoint of treating glaucoma has gradually changed to preserving "visual function" while ensuring minimal effects on QOL in terms of cost, treatment regime, follow-up schedules as well as socio economic burden ([@b20-ppa-2-303]; [@b37-ppa-2-303]).

Patient education and counseling
================================

Having said that, the role of a physician as an educator and counselor to bridge the overwhelming gap in knowledge transfer, cannot be over emphasized. It has been shown that educational interventions that specifically target improving levels of health literacy have a positive influence on subjects' adherence to a therapeutic regime in terms of number of refills obtained more than any other factor such as age, ethnicity, gender, and economic status ([@b32-ppa-2-303]; [@b22-ppa-2-303]). These interventions can be highly successful if conducted at regular intervals in a support group setting as a structured program with an opportunity for patients to discuss various concerns related to disease process and treatment ([@b6-ppa-2-303]; [@b10-ppa-2-303]).

Definitions
===========

Although it is obvious that successful management of POAG depends heavily on patient compliance with a prescribed treatment plan and that compliance with medications has shown to slow the progression of POAG, numerous research studies have also shown that patient behavior towards compliance and adherence to treatment is far from perfect ([@b47-ppa-2-303]). To this end, studies are designed to investigate and gauge patient noncompliance using various measures like patient self-reports, medication possession ratios, pharmacy refills claims data, medication monitors, etc, ([@b39-ppa-2-303]). So when patients state, "I take my eye drops faithfully", how does the practitioner know that they are truly compliant? What is the meaning of the terms "adherence and persistence" that one often reads about in research studies and are they similar to 'compliance'? ([@b4-ppa-2-303]).

Traditionally, most practitioners have viewed compliance as a more "passive" means of taking medication as opposed to adherence that implies a more "active" process in which the patient assumes an active role in making decisions regarding the treatment algorithm. To this end, an extensive literature search revealed that medication compliance and adherence are actually two different terms ([@b4-ppa-2-303]; [@b21-ppa-2-303]). Medication compliance refers to "the degree or extent of conformity to the recommendations of day-to-day treatment by the provider with respect to timing, dosage and frequency." Worded differently it means "the extent to which the patient acts in accordance with the prescribed interval, and dose of a dosing regimen". Hence "compliance" has more to do with the *accuracy* with which a patient follows the treatment plan as opposed to the *extent* to which he/she continues the treatment, which is what "adherence" stands for.

Using this definition, we found that reasons for patient noncompliance to eye-drops can indeed be multifactorial, however the major factors that influence patient attitudes are frequency of application ([@b8-ppa-2-303]; [@b41-ppa-2-303]), ease of use ([@b35-ppa-2-303]; [@b41-ppa-2-303]), comfort ([@b48-ppa-2-303]), tolerability of side effects and perceived benefits ([@b11-ppa-2-303]). For a slowly progressive, non-life-threatening and asymptomatic disease like POAG, long term compliance is a significant issue ([@b47-ppa-2-303]). Most indexing services like MEDLINE and PubMed, select "compliance" as the primary term and "adherence" as a synonym and use it interchangeably. However, if the above-mentioned definitions were to be used to gauge patient medication use and for reporting related research, then "compliance" might be an appropriate term if viewed in the short term and "adherence" appropriate if viewed over a longer period of time.

Persistence, on the other hand, refers to the act of continuing the treatment for the prescribed duration. It may be defined as "the duration of time from initiation to discontinuation of therapy" ([@b21-ppa-2-303]) ([Figure 1](#f1-ppa-2-303){ref-type="fig"}). Consequently, this can only be measured indirectly from past patient records, returned emptied dropper bottles, prescription refill data, and observation of side effects characteristic to the drug prescribed eg, miotic pupils with pilocarpine or long eyelashes with latanoprost on repeated follow-up appointments ([@b7-ppa-2-303]). Other ways of measuring patient persistence would be to directly evaluate patients' IOP controlled days as opposed to a single IOP recording; which would definitely be more accurate but very cumbersome to perform ([@b46-ppa-2-303]).

Interestingly, the National Health Service in UK prefers to use the term "concordance" to involve the patient in the treatment process so that he/she can participate with the provider in treatment decisions as to which course of action to take, and is thereby partially responsible for monitoring and reporting back to the team.

Choice of medical therapy
=========================

Although medical treatment for glaucoma is improving, there is no single perfect therapy. In our opinion, the characteristics of an ideal IOP-lowering eye drop would include: 1. Proven efficacy in reducing IOP consistently over a 24-hour period to a level sufficient to protect the optic nerve and visual field from further damage; 2. Have minimal local and systemic adverse effects; 3. No tachyphylaxis and good tolerance over time; 4. Minimal frequency of dosage in order to promote full patient compliance; and finally, 5. Applicability in diverse patient populations ([@b36-ppa-2-303]). To many caregivers, this would sound akin to a very demanding yet unrealistic list. To date, prostaglandin analogues (PGAs) closely fulfill these criteria in many situations (ie, sustained efficacy, and safety profile with few systemic side effects. Ocular tolerability is generally good, but issues of conjunctival hyperemia, periorbital and iris pigmentation, eyelash growth, etc, do limit applicability in some patients).

In North America, there is a significant trend towards prescribing PGAs as the first-line monotherapy in newly diagnosed POAG ([@b31-ppa-2-303]). These are the most recently introduced class of glaucoma drugs with superior IOP efficacy, once daily dosing and with very minimal systemic side effects. There can however be considerable though not necessarily unpleasant ocular side effects. One study that reviewed three ophthalmology practices in Alberta, Canada found that compared to other first- and second-line forms of therapy, latanoprost either alone or in combination with beta-blockers was associated with greater reductions in IOP, better therapeutic persistence, fewer therapy switches and lesser visits to the ophthalmologist ([@b52-ppa-2-303]). Notwithstanding the above, timolol (Beta-blocker), despite it's contraindications and side-effect profile, is still probably the most used topical glaucoma medication worldwide owing to its availability, lower cost, and long experience ([@b50-ppa-2-303]). In fact, it is one of the first line medications for glaucoma in the developing world.

Despite the good IOP-lowering effect of PGA, some patients may not be well controlled on monotherapy and may require additional medication. This requirement for 2 or more medications is well documented in the major randomized control trials such as the Ocular Hypertension Treatment Study where 49% of patients required more than one medication and the Collaborative Initial Glaucoma Treatment Study where 75% required supplementary medication. For the reader interested in the indications and side effects of the most commonly used antiglaucoma drugs, we have included the summary of the various commonly used antiglaucoma medications as an [appendix](#app1-ppa-2-303){ref-type="app"} at the end of the article. It is important to note that several medications include a dosing regimen that is two, three or even four times daily, thus limiting utility if patients are unable to remember dosing at certain times of day.

Socioeconomic burden
====================

When it comes to evaluating the costs associated with long-term therapy, most studies in literature have evaluated the cost of glaucoma medications by assessing the number of drops per bottle and associated cost per drop or per treatment dose ([@b50-ppa-2-303]; [@b54-ppa-2-303]; [@b42-ppa-2-303]; [@b16-ppa-2-303]; [@b45-ppa-2-303]). A leading study done three years ago that prospectively looked at the expenditure involved in treating glaucoma and OHT over a two-year period in France found that the average daily cost for latanoprost monotherapy was similar to patients who failed beta-blocker monotherapy and that both drugs together did not cost more than therapeutic combinations without latanoprost ([@b43-ppa-2-303]). There are other cost-effectiveness models that compare one of the newer prostaglandin analogues with older medications or with one another. For instance, a newer study done in Canada suggested that for patients in whom timolol is not contraindicated, it would be preferable, from a cost-effectiveness standpoint, to initiate treatment with timolol and reserve the prostaglandin analogues as an alternative treatment or as add-on therapy for patients not achieving a clinical response with timolol. The reasons being, although latanoprost is arguably more effective in its IOP-lowering effects than dorzolamide, brimonidine, or timolol, it is also more expensive ([@b27-ppa-2-303]). However, these studies are at best conflicting in their findings. Their usefulness is limited as they generally evaluate unit medication costs without including differential effectiveness in achieving target IOP or costs associated with rectifying adverse effects of various therapies, and thus they provide only one component of real-world costs for glaucoma. Moreover, there is no universal standard to measure effectiveness outcomes including achieving IOP thresholds, IOP-controlled days ([@b46-ppa-2-303]), percent reduction in IOP and quality adjusted life years (QALYs). Therefore it becomes a daunting task to calculate the actual total expenditure in a cohort population and thereby implement policy decisions supporting the use of one agent versus another.

Additionally, in the developing world, the algorithm of treatment may vary depending on factors such as patient affordability and availability for follow-up. A study done by a tertiary care center in India reported that more than 70% of patients who were on a 3+ drug regime for about 3 years would prefer lasers and surgery because of the cumbersome schedule and financial burden ([@b50-ppa-2-303]). Although latanoprost, travaprost, and brimonidine are effective monotherapies for lowering IOP in eyes with early to moderate POAG, in the long term primary filtering surgery may be a more viable option especially if the patient has a visually significant cataract requiring surgery as well. Considering the paucity of resources and competing opportunity costs, it might be best if developing countries with limited resources examined best practices of the western world in a conservative and cost-effective manner ([@b51-ppa-2-303]). An example of this is the limited use of antimetabolites as an adjunct for primary filtering surgery in the African subcontinent. Despite this, it has been reported that their blebs seem to perform well for longer periods of time as compared to patients of African descent in North America, as the conjunctiva has not been scarred down by the random use of topical hypotensive agents, besides saving on costs for both antimetabolites and long years of topical therapy ([@b15-ppa-2-303]). To aid clinical decision-making taking QOL into account, the American Academy of Ophthalmology developed by panel consensus an assessment for evaluation of therapy related to POAG based on available evidence and expert opinion. By extensive polling, specific guidelines were developed to help practitioners in making clinical decisions regarding switching of therapy, use of adjunctive therapy and assessment/modification of medical therapy with surgery as a primary modality of treatment ([@b49-ppa-2-303]).

Barriers to compliance and persistence
======================================

There are numerous barriers that prevent patients from accessing complete treatment: psychological, socioeconomic, poor health literacy, inadequate information and inadequate patient-provider relationships. Many studies have reported multiple obstacles to adherence in the form of poor education, lack of motivation, forgetfulness, drop application, and other practical issues, together with specific individual and age differences. In fact one study classified the barriers into a four category system and commented that patient compliance was affected by 49% due to social/environmental factors (lack of support, major life events and travel), 32% by regimen factors (complexity, costs and change in medication), 16% by individual patient factors (knowledge, memory, motivation) and 3% by medical provider factors (dissatisfaction, communication) ([Table 1](#t1-ppa-2-303){ref-type="table"}, [Figure 2](#f2-ppa-2-303){ref-type="fig"}). For many patients the source of motivation for adherence is determined by fear of blindness coupled with a faith in drop efficacy ([@b53-ppa-2-303]; [@b26-ppa-2-303]).

A recently completed multicenter study across major cities in Canada assessed the reasons for noncompliance in a questionnaire-based survey. Forgetfulness followed by travel was cited as the most common reason for defaulting on eye drop use ([@b25-ppa-2-303]) ([Figure 3](#f3-ppa-2-303){ref-type="fig"}).

Key strategies to enhance compliance and persistence
====================================================

A number of simple yet effective changes can be implemented to overcome some of these barriers. For instance patients showed improvement in accuracy of reporting medications and hence compliance when given written instructions about their regimen, regardless of their level of education or number of medications ([@b19-ppa-2-303]; [@b24-ppa-2-303]). Providing patients with an easy medication scheduler and reminder in the form of a handout can go long ways to encourage the patient to use the correct eye drops at the appropriate time ([Figure 4](#f4-ppa-2-303){ref-type="fig"}). Similarly, in a highly motivated patient, maintenance of a medication diary can help the health care provider track persistence over time ([@b19-ppa-2-303]; [@b24-ppa-2-303]).

The use of medication monitors, alarm clocks and Travalert^®^ devices has been advocated for patients who need reminders for therapy when traveling ([@b34-ppa-2-303]). For some patients in whom manual dexterity might be compromised the use of an eye guide may aid in accurate instillation of the eye drops without wastage or contamination but it might actually be counter productive in others ([@b44-ppa-2-303]). And although there is no straightforward linear relationship between complexity of eye drop regime and compliance, in some patients, particularly those with memory problems such as Alzheimer's disease prescribing fewer drops may mean better compliance ([@b8-ppa-2-303]). As a rule, it has been found that compliance is enhanced when patients self-medicate. However, if there is a possibility that physical or mental disability might hamper the prospects of self-medication, then involvement of a committed family member or friend in the actual drop instillation process becomes a necessity. Other drivers of patient adherence to topical ocular hypotensive therapy include a healthy communication with professional caregivers, participating in appropriate educational interventions to get information regarding the anticipated natural history with and without treatment and progression of the disease and its consequences, understanding the risks and benefits of treatment in preserving vision-related QOL, and being able to make an informed choice as to available management options ([@b6-ppa-2-303]; [@b12-ppa-2-303]).

Conclusion
==========

This article reviews the various medical approaches to care of patients with POAG. There is an overview of various methods to measure medication compliance and an estimation of the problems related to noncompliance. Emphasis has been laid on the importance of focusing treatment around optimizing patient-related QOL. Lowering IOP to target levels and ensuring compliance and persistency with medical therapy in POAG is fundamental to preventing or slowing glaucomatous visual loss. Similarly, simplification of the treatment regimen, selection of medications with the fewest systemic and ocular side effects, and improving patient-physician relationship can have a significant impact on preventing deterioration due to noncompliance. However, as there are many barriers to effective treatment; it is important to understand these as well as best practices to enhance compliance and persistency in a manner that keeps in mind optimal utilization of finite human and financial resources for the patient, practitioner, and health care system. Some tips to achieve the aforementioned include:

1.  Optimal utilization of evidence-based clinical guidelines for therapy in POAG.

2.  Keep treatment plan straightforward and tailored to patient needs/preferences.

3.  Recognize early in the treatment plan the possible obstacles to compliance and persistence and plan interventions accordingly (eg, low health literacy which can be addressed by patient education sessions).

4.  Monitor progression of disease, quality of life, and institute timely additional intervention(s) as required ([@b17-ppa-2-303]).

The authors would like to thank Dr Daniel Kiage for help with compiling the medication table and Amy Bovell for support with proof reading.

  -------------------------- ------------------------------------------------- ------------------------------------------------------------------ -------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------
  1 Adrenergic agonists                                                                                                                                                                                    

  **Generic**                **Trade name**                                    **Mechanism of action and indications**                            **Properties**                                           **Major side effects and precautions**

                                                                                                                                                                                                           

  Apraclonidine 0.5%--1.0%   Iopidine                                          ↓ Aqueous production\                                              --Max effect in 4 to 5 hrs.\                             **CI:** in children\
                                                                               Prevents severe elevation of IOP following laser procedures        --Duration of effect: 12 hrs.\                           **Side effects:** Dry mouth, lid elevation, allergy \[more with Apraclonidine\] sleepiness, fatigue headaches, Hypotension\
                                                                                                                                                  --↓ IOP by 25%--39%                                      **CI:** in patients with monoamine oxidase inhibitors)

  Brimonidine 0.2%           Alphagan\                                         ↓ Aqueous production\                                              Duration of effect: 8--12 hr\                            
                             Alphagan P (0.15% using Purite as preservative)   ↑ Uveal scleral outflow\                                           TID if monotherapy and BID if adjunctive. ↓ IOP by 27%   
                                                                               Elevation of IOP where IOP can be deleterious to visual function                                                            
  -------------------------- ------------------------------------------------- ------------------------------------------------------------------ -------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------

**Notes:** Several of the above medications are also available as various fixed drug combinations (typically a beta blocker paired with a prostaglandin analogue, carbonic anhydrase inhibitor or alpha-2 agonist). In general, the adverse effects of these combinations are related to the individual drug components.

Applies to all generic drugs under prostaglandin derivatives.

**Abbreviation:** CI, contraindications; SE, side effects; CAI, carbonic anhydrase inhibitors.
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###### 

Taxonomy of barriers to adherence

  Categories                              Sample statement
  --------------------------------------- -----------------------------------------------------------------------------------------------------------------------------
  1\. Region factors                      
   Refill                                 I only forget to take my drops when I run out.
   Cost of medication                     When my insurance stopped paying for my medication I didn't take my drops.
   Complexity                             It was harder when I was taking four medications, now that I am taking three it is better.
   Change                                 When I first started taking the drops I had a harder time remembering.
   Side effects                           I decided to quit taking my drops because I had a bad reaction from them.
  2\. Patient factors                     
   Knowledge/skill                        Sometimes I miss my eye when taking my drops.
   Memory                                 Sometimes I just forget to take my drops.
   Motivation/health beliefs              I quit taking my drops because I didn't see benefit to them and didn't think they were working.
   Co-morbidity                           It is harder to keep track of my drops because I am taking so many other medications.
  3\. Provider factors                    
   Dissatisfaction                        I quit taking my drops because I was dissatisfied with my doctor's care.
   Communication                          I stopped taking my drops because I didn't understand initially that I need to take them forever.
  4\. Situational/environmental factors   
   Accountability/lack of support         Living alone I had problems taking my drops; now I live with my daughter and have no problems.
   Major life events                      Two years ago when my wife died I had a hard time taking my drops.
   Travel/away from home                  When I am on vacation it is more difficult to take my drops.
   Competing activities                   I miss my drops on Sunday mornings when I go to church.
   Change in routine                      Lifestyle changes that occur on the weekends, such as not getting up at a normal hour, cause me to forget to take my drops.

**Note:** Copyright © 2003, Lippincott Williams and Wilkins. Reproduced with permission from [@b53-ppa-2-303]. Compliance barriers in glaucoma: a systematic classification. *J Glaucoma*, 12:393--8.
